The Simplify High Yield PLUS Credit Hedge ETF (CDX) aims to maximize current income through a primary focus on high-yield bonds, while adding a layer of credit risk mitigation. Managed by Simplify Asset Management and listed on NYSE Arca, the fund launched in February 2022 as one of the early ETFs to combine core high-yield exposure with a dedicated credit hedge overlay.
Instead of buying individual bonds, CDX functions as a fund-of-funds. It gains high-yield beta mainly via ETFs and total return swaps tied to benchmarks such as the iShares iBoxx $ High Yield Corporate Bond ETF (HYG), the iShares Broad USD High Yield Corporate Bond ETF (USHY), and the VanEck Fallen Angel High Yield Bond ETF (ANGL). Swaps are collateralized with cash, money-market funds, and short-duration Treasuries, which explains why reported holdings lean heavily toward cash equivalents.
The credit hedge overlay typically mixes CDX index calls, quality-junk factor-based hedges, and S&P 500 put options, chosen based on cost-to-payout ratios. Under normal conditions the fund invests at least 80% of net assets in high-yield securities and may use up to 20% for derivatives. The net expense ratio stands at 0.25%, and the strategy distributes income monthly without issuing a Schedule K-1.
High-yield bonds occupy the space where income demand meets credit risk. Because the asset class leans toward cyclical sectors, ETF results track closely with the credit cycle, movements in Treasury yields, and overall risk appetite.
Structural themes shape the current setting. Elevated rates have lifted yields on cash and short-duration instruments, creating more competition for yield-seeking money. A resilient corporate environment has kept default rates relatively contained, supporting credit spreads near historically tight levels. For a hedged product like CDX, the picture is mixed: the core high-yield sleeve benefits from steady coupon income, yet the cost of maintaining hedges can modestly reduce total return when markets remain calm and volatility stays low.
Monetary policy, inflation data, and refinancing conditions for below-investment-grade issuers continue to drive high-yield fund performance and ETF flows.
CDX has moved within a relatively narrow range in recent months, reflecting the lower volatility profile typical of a hedged fixed-income vehicle. Over the trailing 30 days the fund's price eased roughly 2.2%, while over the trailing quarter it declined approximately 3.9%. Looking further back, the ETF has drifted from levels near $21.20 earlier in the year toward the $19.95 area, a decline of roughly 6% over roughly five months.
This gradual drift aligns with the environment described above. The income-generating core provides some cushion, but rising benchmark yields pressure bond prices and the hedging overlay adds a mild headwind in calm markets. The fund's 52-week range of approximately $19.65 to $22.90 highlights its range-bound character compared with unhedged high-yield funds, which often experience sharper drawdowns during credit shocks and larger rallies in risk-on periods.
Because CDX's high-yield exposure comes through a handful of broad ETFs and swaps, performance depends less on any single issuer and more on the aggregate high-yield market, sector weights across energy, industrials, consumer discretionary, communications, and financials, and the overall behavior of credit spreads. I also checked this using Tickeron’s AI Screener to see how the fund compares with peers in the category.
Several factors are likely to influence CDX over the coming year. The direction of monetary policy and benchmark Treasury yields will affect the value of the fund's high-yield sleeve and the cost of its hedge overlay. Sustained high rates would keep income yields attractive but could pressure bond prices and raise refinancing costs for lower-rated issuers.
Credit conditions remain the key item to monitor. A widening of credit spreads would test the fund's hedging mechanisms and could validate its defensive design, while a continued tightening would favor unhedged competitors. Default and downgrade trends, especially in the cyclical sectors that dominate high-yield indices, deserve attention.
ETF flows and investor positioning in fixed income, along with any regulatory shifts affecting derivatives, could also shape the fund's liquidity and cost structure. In my view, CDX is best seen as an income-oriented, risk-managed way to access high-yield exposure rather than a pure beta play, and its relative performance will hinge on the balance between coupon income, hedging costs, and the path of credit spreads.
I often turn to Tickeron’s AI Screener when evaluating ETFs like CDX. The platform lets me scan securities with technical indicators, fundamentals, volatility measures, and AI-generated signals, making it easier to compare the fund against industry peers and spot relevant patterns without manual effort. It has become a regular part of my research workflow for fixed-income and equity ideas alike.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
CDX's Aroon Indicator triggered a bullish signal on November 02, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 188 similar instances where the Aroon Indicator showed a similar pattern. In 146 of the 188 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 78%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 70 cases where CDX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.
Following a +1.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDX advanced for three days, in 173 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
CDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CDX as a result. In 53 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.
The Moving Average Convergence Divergence Histogram (MACD) for CDX turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 30 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 55%.
CDX moved below its 50-day moving average on October 28, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows